Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative (NQ:XOMAO)

25.31 -0.07 (-0.26%)
Streaming Delayed Price Updated: 11:01 AM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 423
Open 25.37
Bid (Size) 25.31 (800)
Ask (Size) 25.40 (1,200)
Prev. Close 25.38
Today's Range 25.31 - 25.37
52wk Range 23.32 - 25.76
Shares Outstanding N/A
Dividend Yield 8.27%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
XOMA Royalty to Present at Investor Conferences in March
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
Generation Bio Stockholders Received $4.2913 Per Share in Cash Plus a Contingent Value Right 
From XOMA Royalty Corporation
Via GlobeNewswire

Performance

YTD
+0.1%
+0.1%
1 Month
-0.2%
-0.2%
3 Month
-0.2%
-0.2%
6 Month
-1.0%
-1.0%
1 Year
-0.4%
-0.4%

More News

Read More
News headline image
XOMA Royalty Announces CFO Transition
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
From XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
From XOMA Royalty Corporation; LAVA Therapeutics
Via GlobeNewswire
News headline image
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
From XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
From XOMA Royalty Corporation; Turnstone Biologics Corp.
Via GlobeNewswire
News headline image
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
From XOMA Royalty Corporation; BioInvent
Via GlobeNewswire
News headline image
XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Completes Sale of Kinnate Pipeline Assets
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
From XOMA Royalty Corporation
Via GlobeNewswire

Frequently Asked Questions

Is XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative publicly traded?
Yes, XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative is publicly traded.
What exchange does XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative trade on?
XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative trades on the Nasdaq Stock Market
What is the ticker symbol for XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative?
The ticker symbol for XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative is XOMAO on the Nasdaq Stock Market
What is the current price of XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative?
The current price of XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative is 25.31
When was XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative last traded?
The last trade of XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative was at 02/20/26 11:01 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.